ArtsAutosBooksBusinessEducationEntertainmentFamilyFashionFoodGamesGenderHealthHolidaysHomeHubPagesPersonal FinancePetsPoliticsReligionSportsTechnologyTravel

H1N1 Swine Flu Update - Canadian Vaccine & Anaphylaxis

Updated on November 28, 2009

The Glaxo Smith Kline pharmaceutical company released the information that the Canadian provinces that had received particular shipments of H1N1 Mexican Swine flu vaccine to destroy the doses and not use them in their vaccination program. After it was reported that at least 6 cases of allergic reactions leading to anaphylaxis had been reported in individuals who had had vaccination shots from this particular batch.

Anaphylaxis is an allergic reaction which can become very severe and lead to death. The onset of anaphylaxis can be sudden and extreme. The symptoms include swelling of various tissues in the mouth and upper respiratory area, as well as hives and a range of medium to severe cardio vascular problems.

In order for anaphylaxis to be positively identified it has to meet a standard case definition which is an accepted diagnostic criteria stating that the allergic reaction has to affect at least two symptoms in separate organs. In other words the reactions must be a combination of the respiratory system, the cardio vascular system, the skin and any combination thereof.

Anaphylaxis is caused as the result of exposure to a non-pathogenic allergen which has the capability of triggering a response from the patient's immune system. Anaphylaxis is a common allergic reaction to peanuts or pollen in some people.

There is no way to determine why some individuals are allergic to one particular substance and not another. However when a patient presents with an allergic reaction which is directly related to a specific allergen their immune systems begin to generate a very particular kind of antibody that releases significant amounts of histamines into their system.

The histamines which are released due to the allergic reaction are the factors which cause the severe allergic response. The treatment which is recommended for patients which are presenting with anaphylaxis is a form of an adrenaline called epinephrine. Glaxo Smith Kline representatives stated that their expected rate of reactions of an anaphylaxis allergic modality to their influenza shots is approximately 1 in 100,000. They state that anytime that anytime anyone receives an immunization there is always the possibility that an allergic reaction will occur and that a very small number of these individuals will have the allergic reaction of anaphylaxis.

The rate of these reactions of anaphylaxis will vary according to the kind of vaccine used and the demographic profile of the individuals that the vaccine is being given to. Various different locations can also affect the rate of anaphylaxis.

In Australia, higher rates than the average were experienced of anaphylaxis when the HPV vaccine began to be circulated in that country. The Australian health officials were seeing over 2.6 cases of anaphylaxis for every 100,000 people vaccinated for Human Papilloma Virus.

The rates in North America were considerably lower for that same vaccine campaign. By the time Glaxo Smith Kline halted the use of that use of that particular batch of H1N1 Mexican Swine Flu vaccine, over 100,000 doses had already been administered and less than 25,000 doses were still left over. Those were destroyed.

Continued In H1N1 Swine Flu Update - Anaphylaxis Has Also Occurred in MMR & HPV Vaccines

Back To Start


Disclaimer: The information on this Hub page does not constitute medical, legal, commercial, product, and/or service advice or endorsement of any vendor, supplier and/or brand, and does not necessarily reflect the opinion of the author. Listing of an entity or service on this Hub page is not a warranty of the quality or efficacy of the products or services furnished by any entity. The author is not directly compensated by any entity other than the advertising placement services shown on this page.


    0 of 8192 characters used
    Post Comment

    No comments yet.